Antibodies News and Research

RSS

Common spike mutation may make SARS-CoV-2 more susceptible to a vaccine

A new study published in Science confirms that SARS-CoV-2 has mutated in a way that's enabled it to spread quickly around the world, but the spike mutation may also make the virus more susceptible to a vaccine.

12 Nov 2020

Study shows potential of new pinprick blood test for diagnosing HPV-related cancers

A potential breakthrough in the early detection of the neck, head and anal cancers linked to human papilloma viruses has emerged.

12 Nov 2020

Beckman Coulter introduces new SARS-CoV-2 IgM assay in countries accepting the CE Mark

Beckman Coulter, a clinical diagnostics leader, today announced the launch of its Access SARS-CoV-2 Immunoglobulin M assay in countries accepting the CE Mark.

From Beckman Coulter Diagnostics 12 Nov 2020

COVID-19 treatments for people with early infection should be prioritized

COVID-19 treatments for people with early infection are needed urgently, according to a JAMA Viewpoint article by National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony S. Fauci, M.D., and colleagues.

11 Nov 2020

Research shows a unique T cell receptor repertoire in MIS-C patients

Children with coronavirus disease 2019 (COVID-19) sometimes develop the Multisystem Inflammatory Syndrome in Children (MIS-C), which is associated with high morbidity. The underlying T-cell associated mechanism is described by researchers in a new study published on the preprint server bioRxiv in November 2020, as a response to superantigen activation.

11 Nov 2020

Researchers find a better way to block asthma triggers

Every day, ten Americans die from asthma. While quick-acting inhalers and medications can reduce inflammation during an asthma attack, people with asthma have few tools to prevent the next attack from coming.

11 Nov 2020

Spike-based DNA vaccine shows excellent protection against SARS-CoV-2 in a hamster model

A study conducted at the United States Army Research Institute of Infectious Diseases shows how a relatively simple full-length DNA vaccine against spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can elicit neutralizing antibody response in an animal model – even after a single shot with simple jet injection technique.

11 Nov 2020

Low prevalence of SARS-CoV-2 specific antibodies in Lubbock, Texas

A recent study published in the Journal of Primary Care and Community Health has assessed the prevalence of antibodies developed specifically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in front-line workers in Lubbock, Texas. According to the study findings, immunoglobulin G (IgG)-specific anti-SARS-CoV-2 antibodies have been detected in only 0.73% of the participants.

11 Nov 2020

Research tracks humoral immunity response over eight months post COVID-19 infection

Researchers from Chongqing Medical University have tried to answer one of the burning questions regarding the longevity of immune response to coronavirus disease 2019 (COVID-19): How long does immunity last after infection? Their study looked at the lasting effects and continued immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) over eight months after recovery from the infection.

11 Nov 2020

Five important questions about Pfizer’s COVID-19 vaccine

Pfizer's announcement on Monday that its COVID-19 shot appears to keep nine in 10 people from getting the disease sent its stock price rocketing. Many news reports described the vaccine as if it were our deliverance from the pandemic, even though few details were released.

11 Nov 2020

Underrepresented minorities are at increased risk for AL amyloidosis

Despite being theoretically at an increased risk for AL amyloidosis, underrepresented minorities make up only a small percentage of patients seen at specialized treatment centers for this disease.

11 Nov 2020

Critically ill COVID-19 patients experience novel platelet-activating immune complexes, study finds

Canadian researchers from McMaster University, Ontario, have pinpointed platelet activating immune complexes in coagulation disorders associated with coronavirus disease 2019 (COVID-19), the condition caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Nov 2020

Babies can acquire allergies from their mothers in the womb

Mothers can pass on allergies to offspring while they are developing in the womb and that is one reason why babies exhibit allergies early in life, according to a Singapore preclinical study.

10 Nov 2020

Identifying SARS-CoV-2 spike protein mutations resistant to antibodies

Using a set of different monoclonal antibodies, researchers determined different mutations in the SARS-CoV-2 spike protein that leads to resistance. Understanding these resistant mutations is important in developing effective therapeutic strategies.

10 Nov 2020

Lupus Research Alliance announces the 2020 Lupus Innovation Awards

The Lupus Research Alliance proudly announced today the 2020 Lupus Innovation Awards. The projects represent a wide breadth of scientific exploration in lupus, probing the development and progression of lupus while pointing to potential treatment approaches.

10 Nov 2020

New biomaterial significantly reduces scar formation following wounds

Researchers at UCLA, Duke University and other collaborating institutions have developed a biomaterial that may significantly reduce scar formation after wounding, leading to more effective skin healing.

10 Nov 2020

Exosome-mediated mRNA delivery generates broad immune response to multiple SARS-CoV-2 proteins

Recently, researchers from The Johns Hopkins University School of Medicine, Baltimore, MD, USA, and Capricor Therapeutics, Inc., Beverly Hills, CA, USA, described a new approach to SARS-CoV-2 vaccine development using exosomes to deliver mRNAs that encode the antigens from multiple structural proteins of the virus.

9 Nov 2020

After SARS-CoV-2 antibodies fade B and T-cells persist

Now, an international team of thirty researchers from Sweden, Italy, Germany, the USA, and China aimed to determine the longevity of the immune response against SARS-CoV-2, particularly the specific memory B-cell and T-cell responses over time in convalescent COVID-19 patients.

9 Nov 2020

Aspirin to be tested as a potential COVID-19 treatment as part of RECOVERY trial

Now, in new research, the everyday painkiller aspirin will be evaluated as a potential treatment for COVID-19 in one of the United Kingdom’s most significant trials, aiming to evaluate whether it can reduce the risk of blood clots in infected people.

9 Nov 2020

Study suggests herd immunity to COVID-19 in New York City is low

Researchers in the United States have estimated that the proportion of people in New York City who developed antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first wave of the coronavirus disease 2019 (COVID-19) pandemic is around one in eight.

9 Nov 2020